Showing results (201-210 of 293) with videos related to
Sort By:
Pageof 30
The European Respiratory Journal|April 9, 2020
Understanding the pathophysiological mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards personalised treatment approachesSilke Ryan, Eoin P Cummins, Ramon Farre, et al.Biochemical and Biophysical Research Communications|April 2, 2021
The NR4A agonist, Cytosporone B, attenuates pro-inflammatory mediators in human colorectal cancer tissue ex vivoMohamed Ismaiel, Brenda Murphy, Sarah Aldhafiri, et al.Journal of Cell Science|February 8, 2013
A dynamic model of the hypoxia-inducible factor 1α (HIF-1α) networkLan K Nguyen, Miguel A S Cavadas, Carsten C Scholz, et al.Shock (Augusta, Ga.)|August 17, 2011
The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cellsEmily Hams, Sean P Saunders, Eoin P Cummins, et al.American Journal of Physiology. Gastrointestinal and Liver Physiology|October 30, 2016
Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected]Mario C Manresa, Murtaza M Tambuwala, Praveen Radhakrishnan, et al.Immunology and Cell Biology|March 27, 2023
Hypercapnia alters mitochondrial gene expression and acylcarnitine production in monocytesDavid E Phelan, Catarina Mota, Moritz J Strowitzki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)Holly A Massett, Grace Mishkin, Jeffrey A Moscow, et al.Lancet (London, England)|August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studySuresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.Pageof 30